<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://feeds.feedburner.com/~d/styles/itemcontent.css"?><rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" version="2.0">

<channel>
	<title>BioPharmCatalyst</title>
	
	<link>http://www.biopharmcatalyst.com</link>
	<description>Pharmaceutical DataBank</description>
	<lastBuildDate>Fri, 18 May 2012 11:44:47 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	
		<atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" type="application/rss+xml" href="http://feeds.feedburner.com/Biopharmcatalyst" /><feedburner:info uri="biopharmcatalyst" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com/" /><feedburner:emailServiceId>Biopharmcatalyst</feedburner:emailServiceId><feedburner:feedburnerHostname>http://feedburner.google.com</feedburner:feedburnerHostname><item>
		<title>Chatroom has been upgraded – Live now!!</title>
		<link>http://feedproxy.google.com/~r/Biopharmcatalyst/~3/XEOJ7X0KGB0/</link>
		<comments>http://www.biopharmcatalyst.com/2012/05/chatroom-has-been-upgraded-live-now/#comments</comments>
		<pubDate>Fri, 18 May 2012 11:44:47 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Articles]]></category>

		<guid isPermaLink="false">http://www.biopharmcatalyst.com/?p=1728</guid>
		
			<content:encoded><![CDATA[Dear BioPharmCatalyst reader, I am pleased to announce that the chatroom has had a complete revamp for the benefit of all users of BioPharmCatalyst. The previous chatroom was admittedly poorly designed and as a result received little attention. It was not user-friendly and in fact most readers were unaware it existed. However, as of today [...]<br/>
<br/>
[[ This is a content summary. Please visit the website for full information ]]<img src="http://feeds.feedburner.com/~r/Biopharmcatalyst/~4/XEOJ7X0KGB0" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.biopharmcatalyst.com/2012/05/chatroom-has-been-upgraded-live-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		<feedburner:origLink>http://www.biopharmcatalyst.com/2012/05/chatroom-has-been-upgraded-live-now/</feedburner:origLink></item>
		<item>
		<title>NBIX releases Phase 2 data. NBY and SPPI initiate Phase 2 trials</title>
		<link>http://feedproxy.google.com/~r/Biopharmcatalyst/~3/owbQB93axq4/</link>
		<comments>http://www.biopharmcatalyst.com/2012/05/nbix-releases-phase-2-data-nby-and-sppi-initiate-phase-2-trials/#comments</comments>
		<pubDate>Fri, 18 May 2012 09:17:17 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Daily News]]></category>
		<category><![CDATA[NBIX]]></category>
		<category><![CDATA[NBY]]></category>
		<category><![CDATA[SPPI]]></category>

		<guid isPermaLink="false">http://www.biopharmcatalyst.com/?p=1717</guid>
		
			<content:encoded><![CDATA[Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced the initiation of a Phase 2 trial of ZEVALIN for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin&#8217;s lymphoma (NHL). Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced efficacy and safety results from its Phase 2 trial of urocortin 2 in 53 patients [...]<br/>
<br/>
[[ This is a content summary. Please visit the website for full information ]]<img src="http://feeds.feedburner.com/~r/Biopharmcatalyst/~4/owbQB93axq4" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.biopharmcatalyst.com/2012/05/nbix-releases-phase-2-data-nby-and-sppi-initiate-phase-2-trials/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		<feedburner:origLink>http://www.biopharmcatalyst.com/2012/05/nbix-releases-phase-2-data-nby-and-sppi-initiate-phase-2-trials/</feedburner:origLink></item>
		<item>
		<title>Abstracts have been added to the ASCO Calendar!</title>
		<link>http://feedproxy.google.com/~r/Biopharmcatalyst/~3/noxbD6wfpSg/</link>
		<comments>http://www.biopharmcatalyst.com/2012/05/abstracts-have-been-added-to-the-asco-calendar/#comments</comments>
		<pubDate>Thu, 17 May 2012 07:37:15 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Articles]]></category>

		<guid isPermaLink="false">http://www.biopharmcatalyst.com/?p=1713</guid>
		
			<content:encoded><![CDATA[Earlier today abstracts to next month&#8217;s ASCO meeting were released. Approximately 75 of those abstracts can now be found in the BioPharmCatalyst ASCO Calendar, which can be found HERE. Session times and other information can also be found to give you a one-stop resource provided to save you much time in searching for abstracts.<br/>
<br/>
[[ This is a content summary. Please visit the website for full information ]]<img src="http://feeds.feedburner.com/~r/Biopharmcatalyst/~4/noxbD6wfpSg" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.biopharmcatalyst.com/2012/05/abstracts-have-been-added-to-the-asco-calendar/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		<feedburner:origLink>http://www.biopharmcatalyst.com/2012/05/abstracts-have-been-added-to-the-asco-calendar/</feedburner:origLink></item>
		<item>
		<title>ARNA offering. RIGL Phase 2 asthma trial to be initiated this summer</title>
		<link>http://feedproxy.google.com/~r/Biopharmcatalyst/~3/29us7DUbzno/</link>
		<comments>http://www.biopharmcatalyst.com/2012/05/arna-offering-rigl-phase-2-asthma-trial-to-be-initiated-this-summer/#comments</comments>
		<pubDate>Thu, 17 May 2012 07:26:42 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Daily News]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[RIGL]]></category>

		<guid isPermaLink="false">http://www.biopharmcatalyst.com/?p=1710</guid>
		
			<content:encoded><![CDATA[Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced the pricing of an underwritten public offering of 11m shares at a price to the public of $5.50 per share. The gross proceeds to Arena from this offering are expected to be $60.5 million with a 30-day option to offer up to an aggregate of 1,650,000 additional shares. Rigel Pharmaceuticals, Inc., (Nasdaq: RIGL) said [...]<br/>
<br/>
[[ This is a content summary. Please visit the website for full information ]]<img src="http://feeds.feedburner.com/~r/Biopharmcatalyst/~4/29us7DUbzno" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.biopharmcatalyst.com/2012/05/arna-offering-rigl-phase-2-asthma-trial-to-be-initiated-this-summer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		<feedburner:origLink>http://www.biopharmcatalyst.com/2012/05/arna-offering-rigl-phase-2-asthma-trial-to-be-initiated-this-summer/</feedburner:origLink></item>
		<item>
		<title>OSUR positive Adcom vote. SNSS interim data due 3Q. CYTR reverse split.</title>
		<link>http://feedproxy.google.com/~r/Biopharmcatalyst/~3/V7e5yy93Dwg/</link>
		<comments>http://www.biopharmcatalyst.com/2012/05/osur-positive-adcom-vote-snss-interim-data-due-3q-cytr-reverse-split/#comments</comments>
		<pubDate>Wed, 16 May 2012 00:21:39 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Daily News]]></category>
		<category><![CDATA[CYTR]]></category>
		<category><![CDATA[OSUR]]></category>
		<category><![CDATA[SNSS]]></category>

		<guid isPermaLink="false">http://www.biopharmcatalyst.com/?p=1692</guid>
		
			<content:encoded><![CDATA[Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) said today that it is on track to release interim data from its Phase 3 VALOR trial in acute myeloid leukemia, during 3Q 2012. CytRx Corporation (Nasdaq: CYTR) today announced a reverse split of its common stock at a ratio of 1-for-7. CytRx&#8217;s common stock will begin trading on NASDAQ on a split-adjusted [...]<br/>
<br/>
[[ This is a content summary. Please visit the website for full information ]]<img src="http://feeds.feedburner.com/~r/Biopharmcatalyst/~4/V7e5yy93Dwg" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.biopharmcatalyst.com/2012/05/osur-positive-adcom-vote-snss-interim-data-due-3q-cytr-reverse-split/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		<feedburner:origLink>http://www.biopharmcatalyst.com/2012/05/osur-positive-adcom-vote-snss-interim-data-due-3q-cytr-reverse-split/</feedburner:origLink></item>
		<item>
		<title>VTUS releases Phase 3 data. Pipeline updates for ATHX and MDGN</title>
		<link>http://feedproxy.google.com/~r/Biopharmcatalyst/~3/V4n50XRV_6A/</link>
		<comments>http://www.biopharmcatalyst.com/2012/05/vtus-releases-phase-3-data-pipeline-updates-for-athx-and-mdgn/#comments</comments>
		<pubDate>Tue, 15 May 2012 02:06:18 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Daily News]]></category>
		<category><![CDATA[ATHX]]></category>
		<category><![CDATA[MDGN]]></category>
		<category><![CDATA[VTUS]]></category>

		<guid isPermaLink="false">http://www.biopharmcatalyst.com/?p=1670</guid>
		
			<content:encoded><![CDATA[Ventrus Biosciences, Inc. (Nasdaq:VTUS) today reported positive results from its Phase 3 trial of diltiazem hydrochloride cream (VEN 307) in patients with anal fissures.  Both 4% and 2% diltiazem treatment arms demonstrated significant improvements compared to placebo in the primary endpoint of average of worst anal pain associated with or following defecation (pain score improvement 0.44, [...]<br/>
<br/>
[[ This is a content summary. Please visit the website for full information ]]<img src="http://feeds.feedburner.com/~r/Biopharmcatalyst/~4/V4n50XRV_6A" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.biopharmcatalyst.com/2012/05/vtus-releases-phase-3-data-pipeline-updates-for-athx-and-mdgn/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		<feedburner:origLink>http://www.biopharmcatalyst.com/2012/05/vtus-releases-phase-3-data-pipeline-updates-for-athx-and-mdgn/</feedburner:origLink></item>
		<item>
		<title>Pipeline updates for YMI OREX IMMU BDSI FOLD</title>
		<link>http://feedproxy.google.com/~r/Biopharmcatalyst/~3/NEToq8cZ5MQ/</link>
		<comments>http://www.biopharmcatalyst.com/2012/05/pipeline-updates-for-ymi-orex-immu-bdsi-fold/#comments</comments>
		<pubDate>Sat, 12 May 2012 04:28:23 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Daily News]]></category>
		<category><![CDATA[BDSI]]></category>
		<category><![CDATA[FOLD]]></category>
		<category><![CDATA[IMMU]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[YMI]]></category>

		<guid isPermaLink="false">http://www.biopharmcatalyst.com/?p=1660</guid>
		
			<content:encoded><![CDATA[YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM) provided an update today on CYT387 for the treatment of myelofibrosis. It intends to initiate its Phase 3 trial during 2H 2012. By the end of 2012 both final data from its Phase 1/2 Core trial and interim data from the Phase 1/2 Extension trial are expected to be reported. Interim [...]<br/>
<br/>
[[ This is a content summary. Please visit the website for full information ]]<img src="http://feeds.feedburner.com/~r/Biopharmcatalyst/~4/NEToq8cZ5MQ" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.biopharmcatalyst.com/2012/05/pipeline-updates-for-ymi-orex-immu-bdsi-fold/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		<feedburner:origLink>http://www.biopharmcatalyst.com/2012/05/pipeline-updates-for-ymi-orex-immu-bdsi-fold/</feedburner:origLink></item>
		<item>
		<title>ARNA positive Adcom vote. APPA NDA due mid-2012. PATH to resubmit NDA 3Q + TZYM OMER BIOD CTIC MNOV ANAC PBTH updates</title>
		<link>http://feedproxy.google.com/~r/Biopharmcatalyst/~3/PYtrNxwGg8k/</link>
		<comments>http://www.biopharmcatalyst.com/2012/05/arna-positive-adcom-vote-appa-nda-due-mid-2012-path-to-resubmit-nda-3q-tzym-omer-biod-ctic-mnov-anac-pbth-updates/#comments</comments>
		<pubDate>Fri, 11 May 2012 04:10:25 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Daily News]]></category>
		<category><![CDATA[ANAC]]></category>
		<category><![CDATA[APPA]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[BIOD]]></category>
		<category><![CDATA[MNOV]]></category>
		<category><![CDATA[OMER]]></category>
		<category><![CDATA[PATH]]></category>
		<category><![CDATA[PBTH]]></category>
		<category><![CDATA[TZYM]]></category>

		<guid isPermaLink="false">http://www.biopharmcatalyst.com/?p=1651</guid>
		
			<content:encoded><![CDATA[Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 18 to 4, with one abstention, to recommend approval of lorcaserin in patients with obesity. The current PDUFA date is June 27, 2012. However, this may be extended by three months if further data is provided by the company. A.P. Pharma, Inc.(OTCBB:APPA.OB) [...]<br/>
<br/>
[[ This is a content summary. Please visit the website for full information ]]<img src="http://feeds.feedburner.com/~r/Biopharmcatalyst/~4/PYtrNxwGg8k" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.biopharmcatalyst.com/2012/05/arna-positive-adcom-vote-appa-nda-due-mid-2012-path-to-resubmit-nda-3q-tzym-omer-biod-ctic-mnov-anac-pbth-updates/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		<feedburner:origLink>http://www.biopharmcatalyst.com/2012/05/arna-positive-adcom-vote-appa-nda-due-mid-2012-path-to-resubmit-nda-3q-tzym-omer-biod-ctic-mnov-anac-pbth-updates/</feedburner:origLink></item>
		<item>
		<title>VTUS Phase 3 data due May. SCMP sNDA filing soon + Pipeline updates for ASTM OXGN RVX IDRA ARIA</title>
		<link>http://feedproxy.google.com/~r/Biopharmcatalyst/~3/16BV64TKlZA/</link>
		<comments>http://www.biopharmcatalyst.com/2012/05/vtus-phase-3-data-due-may-scmp-snda-filing-soon-pipeline-updates-for-astm-oxgn-rvx-idra-aria/#comments</comments>
		<pubDate>Thu, 10 May 2012 06:34:20 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Daily News]]></category>
		<category><![CDATA[ARIA]]></category>
		<category><![CDATA[ASTM]]></category>
		<category><![CDATA[DVAX]]></category>
		<category><![CDATA[IDRA]]></category>
		<category><![CDATA[OXGN]]></category>
		<category><![CDATA[SCMP]]></category>
		<category><![CDATA[VTUS]]></category>

		<guid isPermaLink="false">http://www.biopharmcatalyst.com/?p=1645</guid>
		
			<content:encoded><![CDATA[Ventrus Biosciences, Inc. (Nasdaq:VTUS) gave a pipeline update noting that initial top-line data from its Phase 3 trial of Diltiazem (VEN 307) in patients with Anal Fissures, is expected to be available in May 2012. Phase 3 data of Iferanserin (VEN 309) in patients with Hemorrhoidal Disease, is expected in late June or early July 2012. Aastrom Biosciences, Inc. (Nasdaq:ASTM) [...]<br/>
<br/>
[[ This is a content summary. Please visit the website for full information ]]<img src="http://feeds.feedburner.com/~r/Biopharmcatalyst/~4/16BV64TKlZA" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.biopharmcatalyst.com/2012/05/vtus-phase-3-data-due-may-scmp-snda-filing-soon-pipeline-updates-for-astm-oxgn-rvx-idra-aria/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		<feedburner:origLink>http://www.biopharmcatalyst.com/2012/05/vtus-phase-3-data-due-may-scmp-snda-filing-soon-pipeline-updates-for-astm-oxgn-rvx-idra-aria/</feedburner:origLink></item>
		<item>
		<title>DCTH NDA expected August. Pipeline updates and news for GTXI SVNT AIS CRIS DCTH MDVN DEPO ACAD ACRX CLVS SGEN</title>
		<link>http://feedproxy.google.com/~r/Biopharmcatalyst/~3/jiBkym6cnc8/</link>
		<comments>http://www.biopharmcatalyst.com/2012/05/dcth-nda-expected-august-pipeline-updates-and-news-for-gtxi-svnt-ais-cris-dcth-mdvn-depo-acad-acrx-clvs-sgen/#comments</comments>
		<pubDate>Wed, 09 May 2012 07:17:49 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Daily News]]></category>
		<category><![CDATA[ACAD]]></category>
		<category><![CDATA[ACRX]]></category>
		<category><![CDATA[AIS]]></category>
		<category><![CDATA[CLVS]]></category>
		<category><![CDATA[CRIS]]></category>
		<category><![CDATA[DCTH]]></category>
		<category><![CDATA[DEPO]]></category>
		<category><![CDATA[DVAX]]></category>
		<category><![CDATA[GTXI]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[SGEN]]></category>
		<category><![CDATA[SVNT]]></category>
		<category><![CDATA[VNDA]]></category>

		<guid isPermaLink="false">http://www.biopharmcatalyst.com/?p=1638</guid>
		
			<content:encoded><![CDATA[Delcath Systems (NASDAQ: DCTH) said that it intends to submit its NDA for its Hepatic CHEMOSAT delivery system in mid-August, 2012. GTx, Inc. (Nasdaq: GTXI) said that the clinical hold placed on Capesaris (GTx-758),for secondary hormonal therapy of advanced prostate cancer, has been lifted by the FDA. The Phase 2 trial will test three lower doses of Capesaris (125 mg, [...]<br/>
<br/>
[[ This is a content summary. Please visit the website for full information ]]<img src="http://feeds.feedburner.com/~r/Biopharmcatalyst/~4/jiBkym6cnc8" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.biopharmcatalyst.com/2012/05/dcth-nda-expected-august-pipeline-updates-and-news-for-gtxi-svnt-ais-cris-dcth-mdvn-depo-acad-acrx-clvs-sgen/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		<feedburner:origLink>http://www.biopharmcatalyst.com/2012/05/dcth-nda-expected-august-pipeline-updates-and-news-for-gtxi-svnt-ais-cris-dcth-mdvn-depo-acad-acrx-clvs-sgen/</feedburner:origLink></item>
	</channel>
</rss>

